Skip to Main Content

KMAP BULLETIN: Positron Emission Tomography (PET) Scan

Date: 12/07/22

KMAP GENERAL BULLETIN 22322 (PDF)

Effective with dates of service on and after January 1, 2023, Positron Emission Tomography (PET) scans, and the radiopharmaceuticals associated with the scans, will be covered for all Medicaid members for oncological indications. Radiopharmaceuticals associated with scans are considered content of service and may not be billed separately. Codes will be covered at 85% of the Medicare rate. Oncological indications are limited to diagnosing, staging, restaging, and monitoring. 

Below PET Scans are eligible for Medicaid Coverage in the following oncological conditions:
PET for Cancers/Tumor TypeDiagnosing & StagingRestaging & Monitoring
Brain CoverCover
Breast (male and female)CoverCover
CervixCoverCover
ColorectalCoverCover
EsophagusCoverCover
Head and Neck (not thyroid, CNS)CoverCover
LymphomaCoverCover
MelanomaCoverCover
MyelomaCoverCover
Non-Small Cell LungCoverCover
OvaryCoverCover
PancreasCoverCover
ProstateNon-CoveredCover
Small Cell LungCoverCover
Soft Tissue SarcomaCoverCover
TestesCoverCover
ThyroidCoverCover
All other cancers not listedCoverCover
All other solid tumorsCoverCover
The following radiopharmaceuticals codes are approved for use with PET for oncologic applications:
A4641 A9515A9552A9587
A9588A9591A9592A9594
A9595 
PET Scan Codes are as follows:
78608788117881278813
788147881578816

Note: The effective date of the policy is January 1, 2023. The implementation of State policy by the KanCare managed care organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.